Birhanu Alemayehu Godana
Institute of Biotechnology, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia.
Clin Proteomics. 2023 Aug 26;20(1):32. doi: 10.1186/s12014-023-09424-x.
Mass spectrometry (MS)-based proteomics have been increasingly implemented in various disciplines of laboratory medicine to identify and quantify biomolecules in a variety of biological specimens. MS-based proteomics is continuously expanding and widely applied in biomarker discovery for early detection, prognosis and markers for treatment response prediction and monitoring. Furthermore, making these advanced tests more accessible and affordable will have the greatest healthcare benefit.This review article highlights the new paradigms MS-based clinical proteomics has created in microbiology laboratories, cancer research and diagnosis of metabolic disorders. The technique is preferred over conventional methods in disease detection and therapy monitoring for its combined advantages in multiplexing capacity, remarkable analytical specificity and sensitivity and low turnaround time.Despite the achievements in the development and adoption of a number of MS-based clinical proteomics practices, more are expected to undergo transition from bench to bedside in the near future. The review provides insights from early trials and recent progresses (mainly covering literature from the NCBI database) in the application of proteomics in clinical laboratories.
基于质谱（MS）的蛋白质组学已越来越多地应用于检验医学的各个学科，以识别和定量各种生物标本中的生物分子。基于MS的蛋白质组学正在不断发展，并广泛应用于生物标志物发现，用于早期检测、预后评估以及治疗反应预测和监测的标志物。此外，使这些先进检测方法更易于获得且价格更可承受将带来最大的医疗效益。这篇综述文章重点介绍了基于MS的临床蛋白质组学在微生物学实验室、癌症研究和代谢紊乱诊断中所开创的新范例。该技术在疾病检测和治疗监测方面比传统方法更具优势，因为它在多重检测能力、卓越的分析特异性和灵敏度以及较短周转时间方面具有综合优势。尽管在基于MS的临床蛋白质组学实践的开发和应用方面取得了一些成就，但预计在不久的将来会有更多实践从实验室走向临床应用。这篇综述提供了蛋白质组学在临床实验室应用的早期试验和最新进展（主要涵盖来自NCBI数据库的文献）的见解。
